Ovarian Neoplasms Clinical Trial
Official title:
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of
chemotherapy of cancer patients for first-line treatment.
2.2 To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients in a
third-line, refractory treatment setting (exclusive of anti-VEGF)
1. 0 Background and Rationale: Despite the use of aggressive treatment protocols, less than
10% of cancer patients with an advanced disease respond to the therapy. There is a
variety of different cancer drug regimens, all of which have approximately the same
probability of clinical effectiveness. Identification of those patients who will or will
not respond to a specific chemotherapy is important for making decisions regarding
chemotherapy regimens as well as alternative management approaches. A laboratory test
that could help to determine the sensitivity of an individual patient's tumor cells to
specific chemotherapeutic agents would be valuable in choosing the optimal chemotherapy
regimen for that patient with an expectation of increasing the response rate to the
therapy. Several types of in vitro assays that measure tumor cell survival following
exposure to cytotoxic agents have been evaluated for their ability to predict
chemotherapy outcomes. As a group, these assays are referred to as drug resistance
assays. In a resistance assay, the surviving tumor cells can be detected directly by
their exclusion or metabolism of specific dyes. Alternatively, since some of tumor cells
are proliferating, their survival can be detected by measurement of DNA synthesis by
radiolabeled precursor incorporation or demonstration of clonogenic potential by growth
into colonies in semi-solid culture medium. In several clinical studies, these assays
were useful in detecting drug resistance and in predicting a poor prognosis for cancer
patients. However, these resistance assays cannot detect sensitivity of an individual
patient's tumor cells to a specific drug. Therefore, new methods determining
drug-sensitivity of the tumor cells of an individual patient and, thus, capable of both
predicting a positive treatment outcome and guiding chemotherapy, would be of
significant value.
Recently, Dr. Kravtsov has developed an automated microculture kinetic (MiCK) assay for
measuring drug induced apoptosis in tumor cells. Apoptosis is a distinct mode of cell death
which occurs under physiological conditions and yet can be induced in malignant cells by
chemical and physical factors including antitumor drugs. During the last decade, it has been
recognized that chemotherapeutic agents exert their antitumor activity by triggering
apoptosis in susceptible tumor cells. This implies that the MiCK assay for apoptosis provides
a mechanism-based approach to studying effects of cytotoxic agents on tumor cells. Unlike
"resistance" assays that measure a fraction of cells surviving drug exposure, the MiCK assay
measures a fraction of tumor cells killed by a chemotherapeutic agent via mechanism of
apoptosis. Therefore the MiCK assay determines drug sensitivity, rather than resistance.
Recently the MiCK assay has been shown to predict complete remission rate and survival in
acute myeloid leukemia patients better than clinical criteria did. In a limited study, the
MiCK assay has been used to direct chemotherapy of the leukemia patients .
The MiCK assay has also been used to study drug-induced apoptosis in solid tumors, including
neuroblastoma and colon adenocarcinoma cell lines. More recent data accumulated by DiaTech
has demonstrated that the MiCK assay can detect drug induced apoptosis in primary cultures of
tumor cells isolated from patients with ovarian carcinoma, gastric carcinoma, metastatic
breast cancer and high grade soft tissue sarcoma. Based on these data, we suggest that the
MiCK assay may be used to detect drug sensitivity profiles of individual patients with
various types of solid tumors. This, in turn, may provide a way to tailor chemotherapy to an
individual patient's drug sensitivity profile, and, thus, improve treatment outcomes,
decrease adverse effects of the chemotherapy, increase the quality of patient's life, and
reduce the treatment cost.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03648489 -
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
|
Phase 2 | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Completed |
NCT02569983 -
The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research
|
||
Withdrawn |
NCT02243059 -
Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
|
Phase 4 | |
Terminated |
NCT02055690 -
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT00415181 -
Pharmacogenomics of Paclitaxel in Ovarian Cancer
|
N/A | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|
||
Completed |
NCT00069160 -
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
|
Phase 2 | |
Completed |
NCT00772863 -
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00046800 -
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
|
Phase 2 | |
Completed |
NCT00035100 -
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
|
Phase 2 | |
Terminated |
NCT00034372 -
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
|
Phase 2 | |
Completed |
NCT00001272 -
A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients
|
Phase 1 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Completed |
NCT02227654 -
Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors
|
N/A | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 |